International Clinical Trial: A randomized, open-label, single-dose, two-formulation, two-sequence, two-period crossover bioequivalence study of canagliflozin tablets under fasting and fed states in healthy subjects

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133557) titled 'A randomized, open-label, single-dose, two-formulation, two-sequence, two-period crossover bioequivalence study of canagliflozin tablets under fasting and fed states in healthy subjects' on Sept. 29.

Study Type: Interventional study

Study Design: Cross-over

Primary Sponsor: Guangzhou Panyu Central Hospital

Condition: Type 2 diabetes mellitus in adult patients

Intervention: Fasting T-R Group:T-R sequence group: In the first period, after overnight fasting for >=10 hours, subjects orally take 1 tablet of the test preparation (canagliflozin tablets, manufactured by Shandong Phoenix Pharmaceutical Co., Ltd., 10...